A study published in the NEJM (March 2025) looked at recurrence of bacterial vaginosis at 12 weeks in two groups: a control group where women received standard treatment but male partners were not treated, and a partner-treatment group. In the partner-treatment group, women received standard treatment, and the male partner received both oral and topical treatment. Male partners in this study received Metronidazole 400 mg BID x 7 days in addition to 2% topical clindamycin cream applied to penile skin BID x 7 days. The trial was actually stopped early as it was found that only treating the female was inferior to treatment of both.
This study concluded that treatment of both the femaleandmale partners led to significantly decreased recurrence of bacterial vaginosis within 12 weeks (35% with dual treatment vs. 65% with female-only treatment). This study suggests that we should consider offering treatment to both sexual partners for patients presenting with bacterial vaginosis.
